Language
English (US)
Arabic
Local Experts Opinion for Pricing Evaluation
What is your entity/ Organization
Please Select
SFDA
NUPCO
NG
KFSH&RC
MODA
MOH
Medical Cities
Clusters
Local Content
Private Centers
Insurance Company
Pharma Company
Medical Device Company
What is your role in the organization?
Back
Next
Clinical Section
To have an added value over existing health technologies with the same labeled indications, the new health technology should be at least?
As effective as the other alternative.
Is 5% -10% more effective.
Is 10%-20% more effective.
Is >20% more effective.
Other
Which source of evidence would you rely upon the most in assessing the clinical value of new health technologies (e.g., drugs or medical devices) for pricing purposes?
Randomized controlled trials that examined the new technology against placebo.
Randomized controlled trials that examined thenew technology against an alternative with thesame labeled indication.
Real-world evidence (e.g., pragmatic trials orlarge observational studies).
Clinical guidelines and expert opinions.
Which of the following outcomes would be the most instrumental in pricing new health technologies for burdensome diseases, such as ischemic heart disease, stroke, and cancer?
Its effectiveness in reducing the overall mortality.
Its effectiveness in delaying progression.
Its favorable tolerability profile.
Its favorable patient-reported outcomes.
Which of the following value-added services would have the most positive clinical impact on patients?
Adherence and disease management programs.
Patient education and support.
Patient lifestyle management.
Physician education and support.
Which of the following factors you would be more likely not to consider in pricing new health technologies?
Surrogate laboratory markers.
Health-related quality of life.
Adherence rates.
Overall survival rates.
Back
Next
Economic Section
From your personal view, which perspective should be given the priority when assessing different health technologies for pricing purposes?
Societal.
Healthcare payer.
Would the reduction in hospitalization rates without impacting the clinical outcomes of the disease result in favorable pricing decision?
Yes, always.
Sometimes, it mainly depends on the diseasestate.
Sometimes, it mainly depends on the committee members’ opinions.
No.
How would you mainly assess the economic impact of new health technology for pricing purposes?
Request economic evaluation from themanufacturer based on certain designated criteria.
Request clinical data from the manufacturerfor in-house economic evaluation.
Review other HTA organizations’recommendations.
Local experts’ opinions.
Which economic evaluation design you value the most in assessing different health technologies for pricing purposes?
Cost effectiveness analysis using naturalunits.
Cost utility analysis using QALYs.
Cost benefit analysis (monetizing outcomes).
Budget impact analysis.
Which of the following international HTA organizations you would trust the most for pricing purposes of new health technologies?
National Institute for Health and CareExcellence (NICE).
Canadian Agency for Drugs and Technologiesin Health (CADTH).
Institute for Clinical and Economic Review(ICER).
National Centre for Pharmacoeconomics(NCPE).
Haute Autorité de santé (HAS).
Which of the followings do you rely upon the most in pricing orphan medicinal products?
International reference pricing.
Internal reference pricing (comparing thenew technology with the current standard ofcare including other prescription drugs).
Unmet need.
Budget impact.
What is the most challenging factor in conducting economic evaluations for new health technologies in Saudi Arabia?
Lack of experts.
Scarcity of data.
Inconsistent pricing practices by the SFDA.
Fragmented healthcare system.
Which type of the managed entry agreements is perceived more favorably in Saudi Arabia?
Outcome-based.
Financial-based.
Which performance based or outcome-based agreements is mostly requested by the payer?
Coverage with evidence development.
Payment by result.
Conditional treatment continuation.
No preference for certain agreement.
Which financial-based agreement is unfeasible in Saudi Arabia?
Volume or expenditure cap.
Conditional rebate/discount.
Free initial treatment.
Price/volume agreement.
Back
Next
Pricing Decision/willingness to pay Section
How much the willingness of the manufacturers to localize the manufacturing impacts the pricing decision?
> 5%
5-10%.
10-20%
>20%.
How much does the council of cooperative health insurance (CCHI) influences the pricing decision at the national level?
> 5%
5-10%.
10-20%
>20%.
Which disease states other than rare medical conditions would be perceived favorably when pricing pharmaceutical products? (You can check more than one box and write down other health conditions)
a. Cancer.
b. Hear conditions.
c. Diabetes.
d. Obesity.
e. Immunological disorders (e.g., rheumatoid
arthritis and psoriasis).
Other
Which of the followings is a reasonable cost effectiveness threshold for Saudi Arabia?
a. SAR 42,046 per QALY.
b. SAR 50,000-75,000 per QALY.
c. SAR 112,125 per QALY (1 GDP per capita).
d. SAR 336,375 per QALY.
Other
What is your willingness to pay for a biosimilar as a percentage of the bio-originator’s price?
a. 80%-90%.
b. 60%-80%.
c. 40%-50%.
Other
What is your willingness to pay for a generic drug as a percentage of the brand drug’s price?
a. 80%-90%.
b. 60%-80%.
c. 40%-50%.
Other
What is your willingness to pay for a generic drug as a percentage of the brand drug’s price?
a. 80%-90%.
b. 60%-80%.
c. 40%-50%.
Other
Submit
Should be Empty: